MEIBOMIAN GLAND EXPRESSION (MGX) TREATMENT: TEARCARE

TearCare system has received 510(k) clearance from the FDA for the treatment of meibomian gland dysfunction. It is a Step 2 DED treatment, and it is a non-invasive 15 minute procedure performed with topical anesthetic drops. It uses localized heat therapy to soften or liquefy thickened meibum inside the glands to allow for more effective gland clearance.

The procedure is followed by the expression of the melted meibum. TearCare procedure improves the function of meibomian glands and protects them long term.

For contact lens wearers, each TearCare procedure often improves wearing time by at least four additional hours. For many of our patients, they report improvement in longer computer work hours and more stable vision. For women patients who wear eye makeup, they report less makeup smearing and watery eyes.

For patients with more severe symptoms, TearCare can be done semi-annually. The procedure is often combined with Microblepharoexfoliation (MBE) Treatment for patients presenting with multiple ocular surface disease (OSD) conditions, including the dry eye disease (DED).